Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?

200611 citationsJournal Article

Authors

Tai‐Juan Aw · Australian Rheumatology Association

Danny Liew · Australian Rheumatology Association

Geoffrey H. Tofler · Royal North Shore Hospital

Hans G. Schneider · Rheumatology Consultants

Marie‐Christine Morel‐Kopp · Australian Rheumatology Association

Baki Billah · Monash University

Henry Krum

Abstract

Rofecoxib therapy results in a significant increase in systolic BP compared to celecoxib. As plasma aldosterone levels were not different between the two drugs, the differential effect of rofecoxib on BP compared to celecoxib appears to be unlikely due to competition by rofecoxib for aldosterone metabolism.

Topics & Keywords

Inflammatory mediators and NSAID effects Hormonal Regulation and Hypertension Eicosanoids and Hypertension Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Hypertension

Volume 24, Issue 10, pp. 1979-1984

DOI: 10.1097/01.hjh.0000244946.80287.3d

Field-Weighted Citation Impact: 0.93